Active Filter(s):
Details:
Under the terms of the agreement, the Company purchased all right, title and interest in the intellectual property owned by the Sellers related to their epidermal growth factor (EGF) platform, including CRES101.
Lead Product(s): CRES101
Therapeutic Area: Rare Diseases and Disorders Product Name: CRES101
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Bioasis
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 16, 2022